- Stocks
- Pharma & Healthcare
- Aspira Pathlab
Aspira Pathlab share price
NSE: ASPIRAPharma & HealthcareDiagnostics & Research
Aspira Pathlab at a glance
With a market capitalisation of ₹125 Cr, it ranks 2539th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was 27.9% in FY25. In Q1 FY26, the quarter ended 30 Jun 2025, revenue was ₹5 Cr (+13.1% year on year) and net profit ₹0 Cr, on a consolidated basis. Promoters held 46.58% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹125 CrRank 2539 on NSE
- Price to book
- 12.12×FY25
- EPS (TTM)
- ₹2.33to Q1 FY26
- ROE
- 27.9%FY25
- ROCE
- 16.0%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 9.4%FY25
- Book value / share
- ₹7.03FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Aspira Pathlab quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr |
| Revenue YoY | — | — | — | — | +13.1% |
| Net profit | −₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | — | — | — | — | — |
| Net margin | −0.4% | 16.0% | 5.7% | 12.5% | 9.0% |
| EPS | ₹0.05 | ₹0.96 | ₹0.30 | ₹0.66 | ₹0.41 |
Aspira Pathlab financials
| Item | FY24 | FY25 |
|---|---|---|
| Revenue | ₹13 Cr | ₹22 Cr |
| Operating profit | −₹3 Cr | ₹2 Cr |
| Net profit | −₹3 Cr | ₹2 Cr |
| EPS (₹) | −₹3.00 | ₹2.00 |
| Cash from operations | ₹1 Cr | ₹2 Cr |
| Total debt | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹6 Cr | ₹8 Cr |
Aspira Pathlab shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 18.39% | 18.39% | 18.39% | 18.39% | 18.39% | 46.58% |
| Non-institutions | 81.61% | 81.61% | 81.61% | 81.61% | 81.61% | 53.42% |
Aspira Pathlab vs peers
The listed Pharma & Healthcare companies nearest to Aspira Pathlab by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PARPar Drugs And Chemicals | ₹105.25 | −2.64% | +1.7% | ₹130 Cr | 9.9 | — |
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
| MAKERSLMakers Labs | ₹209.00 | +0.05% | — | ₹123 Cr | 52.5 | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹21.72 | −2.12% | −50.2% | ₹120 Cr | 83.5 | — |
Ask anything about Aspira Pathlab
Pivot answers on the live chart with evidence you can check, and tests strategies against ASPIRA's own history. Try: “Why has ASPIRA moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASPIRA over five years” · “Compare ASPIRA with PAR on margins and valuation”
Frequently asked questions about Aspira Pathlab
What is the market cap of Aspira Pathlab?
Aspira Pathlab's market capitalisation is ₹125 Cr (₹125 Cr) at the 19 Oct 2026 close, ranking 2539th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Aspira Pathlab?
Return on equity was 27.9% in FY25 and return on capital employed was 16.0% in FY25 (consolidated figures).
Is Aspira Pathlab a debt-free company?
Aspira Pathlab is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Aspira Pathlab's latest quarterly results?
For Q1 FY26 (quarter ended 30 Jun 2025), Aspira Pathlab reported revenue of ₹5 Cr, +13.1% year on year, and net profit of ₹0 Cr.
What is the shareholding pattern of Aspira Pathlab?
As of 30 Jun 2026: promoters 46.58%, non-institutions 53.42%.
Who are Aspira Pathlab's competitors?
The listed Pharma & Healthcare companies closest to Aspira Pathlab by market cap are Par Drugs And Chemicals, Parnax Lab, Krebs Biochemicals and Industries, Makers Labs, Godavari Drugs and BALAXI PHARMACEUTICALS.
Is Aspira Pathlab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aspira Pathlab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASPIRA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text